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Summary
Background Multiple myeloma has been shown to have substantial clonal heterogeneity, suggesting that agents with 
different mechanisms of action might be required to induce deep responses and improve outcomes. Such agents 
could be given in combination or in sequence on the basis of previous response. We aimed to assess the clinical value 
of maximising responses by using therapeutic agents with different modes of action, the use of which is directed by 
the response to the initial combination therapy. We aimed to assess response-adapted intensification treatment with 
cyclophosphamide, bortezomib, and dexamethasone (CVD) versus no intensification treatment in patients with 
newly diagnosed multiple myeloma who had a suboptimal response to initial immunomodulatory triplet treatment 
which was standard of care in the UK at the time of trial design.
Methods The Myeloma XI trial was an open-label, randomised, phase 3, adaptive design trial done at 110 National 
Health Service hospitals in the UK. There were three potential randomisations in the study: induction treatment, 
intensification treatment, and maintenance treatment. Here, we report the results of the randomisation to 
intensification treatment. Eligible patients were aged 18 years or older and had symptomatic or non-secretory, newly 
diagnosed multiple myeloma, had completed their assigned induction therapy as per protocol (cyclophosphamide, 
thalidomide, and dexamethasone or cyclophosphamide, lenalidomide, and dexamethasone) and achieved a partial or 
minimal response. For the intensification treatment, patients were randomly assigned (1:1) to cyclophosphamide 
(500 mg daily orally on days 1, 8, and 15), bortezomib (1·3 mg/m² subcutaneously or intravenously on days 1, 4, 8, 
and 11), and dexamethasone (20 mg daily orally on days 1, 2, 4, 5, 8, 9, 11, and 12) up to a maximum of eight cycles of 
21 days or no treatment. Patients were stratified by allocated induction treatment, response to induction treatment, and 
centre. The co-primary endpoints were progression-free survival and overall survival, assessed from intensification 
randomisation to data cutoff, analysed by intention to treat. Safety analysis was per protocol. This study is registered 
with the ISRCTN registry, number ISRCTN49407852, and clinicaltrialsregister.eu, number 2009–010956–93, and has 
completed recruitment.
Findings Between Nov 15, 2010, and July 28, 2016, 583 patients were enrolled to the intensification randomisation, 
representing 48% of the 1217 patients who achieved partial or minimal response after initial induction therapy. 
289 patients were assigned to CVD treatment and 294 patients to no treatment. After a median follow-up of 
29·7 months (IQR 17·0–43·5), median progression-free survival was 30 months (95% CI 25–36) with CVD and 
20 months (15–28) with no CVD (hazard ratio [HR] 0·60, 95% CI 0·48–0·75, p<0·0001), and 3-year overall survival 
was 77·3% (95% Cl 71·0–83·5) in the CVD group and 78·5% (72·3–84·6) in the no CVD group (HR 0·98, 95% CI 
0·67–1·43, p=0·93). The most common grade 3 or 4 adverse events for patients taking CVD were haematological, 
including neutropenia (18 [7%] patients), thrombocytopenia (19 [7%] patients), and anaemia (8 [3%] patients). No 
deaths in the CVD group were deemed treatment related.
Interpretation Intensification treatment with CVD significantly improved progression-free survival in patients with 
newly diagnosed multiple myeloma and a suboptimal response to immunomodulatory induction therapy compared 
with no intensification treatment, but did not improve overall survival. The manageable safety profile of this 
combination and the encouraging results support further investigation of response-adapted approaches in this 
setting. The substantial number of patients not entering this trial randomisation following induction therapy, 
however, might support the use of combination therapies upfront to maximise response and improve outcomes as is 
now the standard of care in the UK.
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Introduction
The aetiology and progression of multiple myeloma are 
driven by the accumulation of acquired genetic events 
that affect clonal competition within the bone marrow 
microenvironment.1,2 Tumour cell diversity increases as 
genetic lesions accumulate, and the disease progresses 
from monoclonal gammopathy of undetermined signif­
icance to myeloma, leading to substantial subclonal 
heterogeneity at the time of diagnosis. Applying induction 
treatment designed to eliminate susceptible clones might 
provide selective pressure for the expansion of resistant 
clones, resulting in early or late relapse. Combination 
chemotherapies designed to maximise tumour cell death 
and eliminate resistant clones can improve clinical 
outcomes compared with single­agent chemotherapies. 
Depth of response has been identified as an independent 
prognostic factor, making the eradication of minimal 
residual disease an important therapeutic endpoint.3–5
Strategies to deepen response after induction therapy 
include the use of autologous haemopoietic stem cell 
transplantation (in those eligible) and the use of post­
transplant consolidation therapy. Although the optimal 
timing for achieving maximum response is unclear, in 
our previous study, Myeloma IX,6,7 patients with complete 
response before transplantation had better progression­
free survival and overall survival than patients without 
complete response, supporting an argument for early 
achievement of deep responses and the use of pre­
transplant intensification rather that post­transplant 
consolidation.
This association raises the question as to whether 
monitoring response during induction therapy and 
switching to an alternative chemotherapy regimen in 
poor responders could increase the rate and depth of 
response and improve clinical outcomes. This study is 
the first to prospectively evaluate such a response­
adapted approach to induction therapy for patients with 
newly diagnosed multiple myeloma. The purpose of the 
trial was to determine whether treatment intensification 
with a bortezomib­based regimen improves progression­
free survival and overall survival in patients with 
suboptimal response after immunomodulatory­drug–
based induction therapy, which was standard of care in 
the UK at time of trial design.
Research in context
Evidence before this study
Potential strategies to deepen response after induction therapy 
for patients with myeloma include the use of autologous 
haemopoietic stem cell transplantation (in those eligible) and the 
use of post-transplant consolidation. Although the optimal 
timing for achieving maximum response is unclear, we found in 
our previous study, Myeloma IX, that patients with a complete 
response before autologous haemopoietic stem cell 
transplantation had better progression-free and overall survival 
than patients with a less than complete response. This supports 
an argument for early achievement of deep responses and the use 
of pre-transplant intensification rather than post-transplant 
consolidation. Little data is available concerning strategies for 
deepening response in transplantation-ineligible patients. 
We searched PubMed (July 15, 2019) for trials examining a 
response-adapted intensification strategy, using the search terms 
“myeloma” and “intensification”, without language restrictions, 
for clinical trials published before 2019 and excluding those 
relating to the introduction of autologous haemopoietic 
stem cell transplantation or those lacking response 
adaptation. We identified one previous phase 2 study reporting 
the use of cyclophosphamide, bortezomib and dexamethasone 
intensification administered to eight patients who failed to 
achieve more than a partial response to two cycles of 
cyclophosphamide, thalidomide and dexamethasone induction 
therapy. Five (63%) of eight deepened their response. To our 
knowledge the strategy of early response-adapted therapy has 
not been previously studied in a randomised trial and we sought 
to investigate this in Myeloma XI.
Added value of this study
We found a significant improvement in response and 
progression-free survival associated with the use of proteasome 
inhibitor-based intensification therapy for patients who achieved 
only a minimal or partial response to immunomodulatory triplet 
induction for newly diagnosed myeloma patients, although no 
difference in overall survival occurred.
Implications of all the available evidence
Our results support the concept that resistance to initial therapy 
is based on the specific therapy used and can be overcome by 
switching to a chemotherapy regimen with an alternate 
mechanism of action. In the event of a suboptimal response to 
immunomodulatory agent-based induction therapy, switching 
to a proteasome inhibitor-based combination improved 
response and progression-free survival. Taken together our data 
suggest that if agents of several different classes are available 
and can be tolerated in combination they should be used 
together upfront as is now the standard of care in the UK. If not, 
agent class should be switched rapidly in the absence of a deep 
response with the aim of response intensification to prolong 
progression-free survival.
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Methods
Study design and participants
The Myeloma XI study was a phase 3, open­label, 
randomised, adaptive design trial with three rando misation 
stages (figure 1). There were three potential randomisations 
in the study: at trial entry for all patients to allocate 
induction treatment separately for those considered eligible 
or ineligible for transplantation; after induction treatment 
for those patients with a suboptimal response to treatment 
(minimal or partial response based on International 
Myeloma Working Group response criteria) to allocate 
induction intensification treatment; and at the completion 
of induction and intensification or autologous haemopoietic 
stem cell transplantation (where applicable) to allocate 
maintenance treatment. This Article reports the results of 
the randomisation to induction intensification treatment. 
Results of the induction and maintenance randomisations 
have been,8 or will, be presented elsewhere. The trial 
recruited from 110 National Health Service hospitals in 
England, Wales, and Scotland (appendix p 15).
Figure 1: Trial profile of Myeloma XI
Area highlighted is the CVD randomisation reported in this manuscript. C=cyclophosphamide. D=dexamethasone. R=lenalidomide. T=thalidomide. V=bortezomib.
1217 achieved partial or minimal response
583 randomly assigned to induction 
intensification
634 excluded
 37 ineligible
 130 died
 78 had disease 
progression
 302 withdrew consent
 62 proceeded to 
autologous 
stem-cell transplant
 25 proceeded to 
maintenance
randomisation 
289 assigned to CVD 294 assigned to no 
CVD 
239 achieved stable or progressive disease
135 assigned to CVD
2052 achieved complete or very good
partial response
1274 received autologous stem-cell transplant where applicable
1858 included in maintenance randomisation
3894 participants randomly assigned
1945 participants assigned to CRD or attenuated CRD 1949 participants assigned to CTD or attenuated CTD
3623 assessed for response
115 unable to be assessed
156 patients were not evaluated for response
694 assigned to observation 857 assigned to lenalidomide 307 assigned to lenalidomide 
plus vorinostat
See Online for appendix
Articles
e619 www.thelancet.com/haematology   Vol 6   December 2019
Eligible patients for the overall study were at least 
18 years of age and had newly diagnosed multiple 
myeloma, based on paraprotein in serum or urine, bone 
marrow clonal plasma cells or plasmacytoma, and 
myeloma­related symptoms or organ or tissue impair­
ment. Eligible patients for the intensification random­
isation reported here additionally had to have  completed 
their assigned induction therapy as per protocol 
(cyclophosphamide, thalidomide, and dexa methasone or 
cyclophosphamide, lenalidomide, and dexamethasone) 
and achieved a partial or minimal response. Patients were 
excluded at trial entry if they had other previous or 
concurrent malignancies, including myelo dysplastic 
syndromes, previous treatment for myeloma (excluding 
local radiotherapy, bisphosphonates, and corticosteroids), 
grade 2 or higher peripheral neuropathy, acute renal 
failure (unresponsive to up to 72 h of rehydration, 
characterised by creatinine >500 µmol/L or urine output 
<400 mL per day, or requiring dialysis), or active or 
previous hepatitis C infection. The study was approved by 
the national ethics review board (National Research Ethics 
Service, London, UK), institutional review boards of the 
participating centres, and the competent regulatory 
authority (Medicines and Healthcare Products Regulatory 
Agency, London, UK), and was done according to the 
Declaration of Helsinki and the principles of Good 
Clinical Practice as espoused in the Medicines for Human 
Use (Clinical Trials) Regulations. The study was not 
originally designed as an adaptive trial however good 
recruitment and the emergence of data on novel 
combinations led to trial adaptation. These changes were 
proposed by the Trial Management Group and approved 
by the independent Data Monitoring and Ethics 
Committee and Trial Steering Committee. The final study 
protocol is in the appendix (p 19). All patients provided 
written informed consent.
Randomisation and masking
Patients considered eligible for transplantation at trial 
entry were randomly assigned (1:1) to induction treatment 
with either cyclophosphamide, thalidomide, and dexa­
methasone (CTD) or cyclophosphamide, lenalido mide, 
and dexamethasone (CRD). A computer­generated mini­
misation algorithm with a random element was used to 
avoid chance imbalances in six variables measured at trial 
entry: β2­microglobulin (<3·5 mg/L vs 3·5–<5·5 mg/L vs 
≥5·5 mg/L vs unknown), haemoglobin (<115 g/L vs 
≥115 g/L for men; <95 g/L vs ≥95 g/L for women), 
corrected serum calcium (<2·6 mmol/L vs ≥2·6 mmol/L), 
serum creatinine (<140 μmol/L vs ≥140 μmol/L), platelets 
(<150 × 10⁹ cells per L vs ≥150 × 10⁹ cells per L), and centre 
(each centre is listed in the appendix p 15). Following a 
protocol amendment on June 28, 2013, and after the 
recruitment of 1512 patients, patients considered eligible 
for transplantation were randomly assigned (1:1:2) to 
CTD, CRD, or carfilzomib, cyclophosphamide, 
lenalidomide, and dexamethasone (KCRD). A similar 
minimisation algorithm with a random element was 
used to avoid chance imbalances in the six variables 
measured at trial entry. These changes were made to add 
a new induction treatment research question to this 
adaptive design study and were approved by the 
independent Data Monitoring and Ethics Committee and 
Trial Steering Committee. Patients considered ineligible 
for trans plantation at trial entry were randomly assigned 
(1:1) to induction with either attenuated CTD or attenuated 
CRD. A similar mini misation algorithm with a random 
element was used to avoid chance imbalances in the six 
variables measured at trial entry.
Patients with a suboptimal response to induction 
treatment were randomly assigned (1:1) to cyclophos­
phamide, bortezomib, and dexamethasone (CVD) or no 
CVD. A minimisation algorithm with a random element 
was used to avoid chance imbalances in three variables: 
allocated induction treatment (CTD vs CRD vs attenuated 
CTD vs attenuated CRD), response to induction treatment 
(minimal or partial response), and centre. Patients 
allocated to KCRD induction treatment were ineligible 
for this randomisation.
Patients completing induction and intensification 
treatment (where applicable) and eligible were randomly 
assigned (1:1) to lenalidomide maintenance or obser­
vation. A minimisation algorithm with a random element 
was used to avoid chance imbalances in three variables: 
allocated induction treatment (CTD vs CRD vs attenuated 
CTD vs attenuated CRD), allocated intensifi cation treat­
ment (no CVD vs CVD vs not randomly assigned at 
intensification randomisation), and centre. Following a 
protocol amendment on Sep 14, 2011, and after 
recruitment of 442 patients under protocol 
versions 2.0 to 4.0, patients were randomly assigned 
(1:1:1) to lenalidomide, lenalidomide plus vorinostat, or 
observation. A similar minimisation algorithm with a 
random element was used to avoid chance imbalances in 
the same three variables with the same categories. 
Following a protocol amendment on June 28, 2013, and 
after recruitment of 615 further patients under protocol 
version 5.0, patients were randomly assigned (2:1) to 
lenalidomide or observation. A similar minimisation 
algorithm with a random element was used to avoid 
chance imbalances in the same three variables with the 
same categories but with the addition of KCRD to the 
induction treatment options. These changes were made 
to add and remove research questions in maintenance in 
this adaptive design study and were approved by the 
independent Data Monitoring and Ethics Committee and 
Trial Steering Committee.
All randomisations were done at the Clinical Trials 
Research Unit (Leeds, UK) by authorised members of 
staff with a centralised automated 24­h telephone system 
according to a validated minimisation algorithm 
produced under the supervision of WMG. Because of the 
nature of the intervention, the study was open label and 
the allocated treatment was not masked from study 
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investigators or patients. The funders remained masked 
to treatment results until data cutoff.
Procedures
The dose, schedule, and route of administration of each 
drug included in the induction, intensification, and main­
tenance regimens are described in the appendix (p 3). 
Briefly, in transplantation­eligible patients, induction 
therapy with CTD, CRD, or KCRD continued for at least 
four cycles in the absence of progressive disease, until 
maxi mum response or intolerance was observed. In trans­
plantation­ineligible patients, attenuated CTD or atten­
uated CRD continued for at least six cycles in the absence 
of progressive disease, until maximum response or intol­
erance was observed. Attenuated versions of induction 
included lower doses of dexamethasone and a lower 
starting dose of thalidomide. For all patients, bisphos­
phonates were recommended until progressive disease 
and thromboprophylaxis was recommended for at least 
the first 3 months of treatment as per International 
Myeloma Working Group recommendations. Growth 
factor support and prophylaxis for pneumonia, varicella, 
fungal infection, and tumour lysis syndrome were allowed 
as per local practice.
Transplantation­eligible patients receiving KCRD pro­
ceeded to high­dose melphalan and autologous haemo­
poietic stem cell transplantation. Patients receiving 
immuno modulatory­based triplets (CTD vs CRD) followed 
a response­adapted approach with induction treatment 
intensification: those with complete response or very good 
partial response (assessed according to International 
Myeloma Working Group criteria) proceeded to trans­
plantation in the transplantation­eligible pathway, whereas 
transplantation­ineligible patients proceeded directly to 
maintenance random isation.
Transplantation­eligible and transplantation­ineligible 
patients allocated to induction treatment intensification 
received cyclophosphamide (500 mg daily orally on 
days 1, 8, and 15), bortezomib (1·3 mg/m² subcutaneously 
or intravenously on days 1, 4, 8, and 11), and dexa­
methasone (20 mg daily orally on days 1, 2, 4, 5, 8, 9, 11, 
and 12) up to a maximum of eight cycles of 21 days in the 
absence of progressive disease, until maximum response 
or intolerance was observed. Full details of the dose 
reduction schedules are shown in the appendix (p 4).
For maintenance therapy, 100 days after autologous 
haemopoietic stem cell transplantation or once a 
maximum response was achieved for transplantation­
ineligible patients, patients initially received lenalid­
omide or were observed without lenalidomide therapy. 
Following a protocol amendment on Sep 14, 2011, and 
after recruitment of 442 patients, patients were allocated 
(1:1:1) to receive lenalidomide, lenalidomide plus 
vorinostat, or observation. After recruitment of 615 more 
patients, a further protocol amendment on June 28, 2013, 
allocated patients to receive lenalidomide or observation 
in a 2:1 ratio, and the lenalidomide plus vorinostat group 
was discontinued. Maintenance treatment continued 
until progressive disease in the absence of toxicity.
Response and disease progression were assessed on 
the basis of International Myeloma Working Group 
Uniform Response criteria9–11 and reviewed centrally by 
an expert panel masked to treatment allocation. Adverse 
events were graded according to the US National Cancer 
Institute Common Terminology Criteria for Adverse 
Events version 4.0.
Adverse reactions were assessed at the start of each 
treatment cycle in patients receiving induction intensifi­
cation. Comparisons between randomised groups were 
not made as adverse reactions could not be collected for 
those allocated to no CVD. Serious adverse events were 
reported for all patients from the date of randomisation 
until 30 days after the date of disease progression except 
in the case of serious adverse reactions or second primary 
malignancies, which were collected for the duration of 
the trial. Comparisons of these events were made 
for induction and maintenance comparisons only. 
Paraprotein, serum­free light chain, and urinary light 
chain excretion were assessed at least every 2 months for 
the first 2 years and then at least every 3 months until 
disease progression.
Cytogenetic risk profiling was done by use of multiplex 
ligation­dependent probe amplification using DNA and 
real­time PCR (rtPCR) using RNA, which were extracted 
from CD138­selected plasma cells from bone marrow 
biopsy samples taken before treatment initiation. rtPCR 
was used to assess the expression of translocation gene 
partners including t(4;14):MMSET, FGFR3, t(14;16):MAF, 
and t(14;20):MAFB. Multiplex ligation­dependent probe 
amplification was used to assess copy number aberrations 
by including probe sets at sites of the commonly deleted 
or amplified regions in myeloma (eg, at genes CKS1B on 
1q21.3 and TP53 on 17p13). These techniques are validated 
and provide equivalent results to interphase fluorescence 
in­situ hybridisation.12–14 Patients were classified into three 
cytogenetic risk groups for the preplanned analysis of 
outcomes: standard risk (no adverse cytogenetic 
abnormalities), high risk (one adverse cytogenetic 
abnormality), or ultra­high risk (two or more adverse cyto­
genetic abnormalities). Adverse cytogenetic abnormalities 
were defined as gain(1q), t(4;14), t(14;16), t(14;20), or 
del(17p).15,16
Outcomes
The co­primary endpoints of the induction intensification 
evaluation of the trial were progression­free and overall 
survival. Progression­free survival was defined as the 
time from induction intensification randomisation to 
progressive disease or death from any cause. Overall 
survival was defined as the time from induction 
intensification to death from any cause or last follow­up.
Secondary endpoints were response (including the 
proportion of conversions from minimal or partial 
response to very good partial response or better in 
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patients allocated to CVD), progression­free survival 2 
(defined as the time from induction intensification 
randomisation to the date of second progressive disease, 
start of third antimyeloma treatment, or death from any 
cause), and toxicity.
Exploratory analyses of progression­free survival, 
overall survival, and response by cytogenetic risk group 
were prespecified in the protocol and by induction 
treatment were prespecified in the statistical analysis 
plan within each pathway. Other exploratory endpoints 
will be reported elsewhere.
Statistical analyses
The data cutoff date for this analysis was Jul 28, 2016. 
The hypothesis of the induction intensification 
randomisation was that CVD treatment could improve 
progression­free survival and overall survival compared 
with no CVD in adult patients with newly multiple 
myeloma. The overall study includes PFS and overall 
survival as co­primary endpoints for each randomisation. 
However, for the intensification element of the study 
only PFS was powered.
For PFS in the transplantation­eligible pathway, the 
trial was designed to show a 9­month increase in median 
progression­free survival in the CVD group (median 
35 months) compared with the no CVD group 
(median 26 months, hazard ratio [HR] 0·74) when a total 
of 361 progression­free survival events had been 
observed. This calculation assumed the time­to­event 
was exponentially distributed and that recruitment would 
last 4 years with a further 4 years of follow­up, a two­sided 
5% significance level, and 80% power. A recruitment 
target of 476 patients randomly assigned (1:1) to CVD or 
no CVD in the transplantation­eligible pathway was 
specified, allowing for 5% dropout. For progression­free 
survival in the transplantation­ineligible pathway, the 
trial was designed to demonstrate a 6­month increase 
in median progression­free survival in the CVD group 
(median 14 months) compared with the no CVD group 
(median 20 months, HR 0·70) when 337 PFS events had 
been observed. This calculation was based on similar 
assumptions but with a two­sided 5% significance level 
and 90% power. A recruitment target of 380 patients 
randomly assigned (1:1) to CVD or no CVD in the 
transplantation­eligible pathway was specified, allowing 
for 5% dropout. No power calculations were specified for 
the overall survival endpoint and analysis was triggered 
by induction analysis. The trial was designed assuming 
47% of patients would be eligible following suboptimal 
response in each treatment pathway. These assumptions 
and estimated outcomes without CVD were based on 
results from our previous study, Myeloma IX.7
Efficacy analyses were done by intention to treat, 
including all patients randomly assigned to either CVD or 
no CVD. The safety population included all patients who 
received at least one dose of CVD therapy or those 
assigned to no CVD. For the co­primary endpoints, we 
estimated summaries of time to event per treatment 
group using the Kaplan­Meier method. We made 
comparisons between the allocated groups using the 
Cox proportional hazards model adjusted for the 
minimisation stratification factors, excluding centre, and 
stratified by treatment pathway, to estimate HRs and 
95% CIs. Subgroup analysis was prespecified for the 
presence or absence of individual adverse cytogenetic 
abnormalities, cytogenetic risk status, and induction 
treatment. We did a likelihood ratio test for heterogeneity 
of treatment effect using Cox models identical to those 
used for the main analysis, with the inclusion of terms for 
the subgroup in question and the appropriate interaction 
terms. The reported test for heterogeneity for subgroup 
analysis corresponds to a one degree of freedom test for 
two category subgroups and a two degrees of freedom test 
for three category subgroups, etc. The number and 
proportion of participants in each response category was 
summarised descriptively and exact 95% CIs calculated 
using the Clopper­Pearson method. We summarised 
toxicity, in terms of adverse events, descriptively.
Post­hoc exploratory analyses were the effect of CVD on 
progression­free survival and overall survival within the 
subgroups sex, age, and disease stage according to the 
International Staging System. The proportional hazards 
assumptions were assessed by plotting the hazards over 
time (ie, the log cumulative hazard plot) for each 
treatment group, the methods described by Lin and 
colleagues17 were used to check the adequacy of the Cox 
regression model. Evidence was found to support a 
violation of the proportional hazards assumption in 
the progression­free survival comparison. Post­hoc 
exploratory analysis using restricted mean survival time 
methods18 was used to compare PFS times in the 
transplantation­eligible pathway. The parameter t* (ie, the 
area under the survival curve up to a time horizon) in 
the restricted mean survival time estimation, the expected 
progression­free period in this study, was chosen to be 
64 months, because this was the maximum follow­up for 
all patients in the study. Other values of t* were 
investigated for the transplantation­ineligible pathway.
Formal interim analyses were prespecified in the study 
protocol for response and progression­free survival. 
A formal interim analysis was prespecified in the study 
protocol to ensure at least a 15% conversion of partial and 
minimal response patients to complete or very good 
partial response. The number of conversions was reviewed 
by the Myeloma XI data monitoring and ethics committee 
after one response in 19 patients who had completed CVD 
treatment, three in 50, and 22 in 200, with prespecified 
stopping criteria determined using exact probabilities for 
a Gehan two­stage design with 95% power.19 Additionally, 
at the last of these interim analyses, the possibility of an 
exceptionally large early effect of CVD on outcomes was 
evaluated using prespecified criteria of a 50% conversion 
or an increase in median progression­free survival of 
24 months compared with no CVD (45 vs 21 months; 
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HR 0·47). To ensure an overall significance level of 
0·05 was maintained, the O’Brien and Fleming alpha­
spending function was used with prespecified bounds of 
0·005 for interim and 0·047 for final analysis.20 The interim 
analysis was done and presented to the data monitoring 
and ethics committee on Nov 14, 2014, and the study 
continued without reporting the interim analysis. All 
reported p values are two sided and considered significant 
at an overall significance level of 5%.
We used SAS (version 9.4), Stata/IC (version 14.2), and 
R (version 3.2.3) for statistical analyses. This study is 
registered with the ISRCTN registry, number 
ISRCTN49407852, and clinicaltrialsregister.eu, number 
2009­010956­93.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Of 3894 patients enrolled in the triplet induction element 
of the trial, 1217 achieved partial response or minimal 
response after induction therapy, of whom 583 (48%) 
were randomly assigned to CVD or no CVD in the 
intensification randomisation. Reasons for exclusion 
before intensification randomisation included withdrawn 
consent (n=302), ineligibility (n=37), proceeded directly to 
autologous haemopoietic stem cell transplantation 
(n=62), proceeded directly to maintenance therapy (n=25), 
progressive disease (n=78), and death (n=130). Slightly 
higher attrition occurred in the transplantation­ineligible 
pathway than transplantation­eligible but no difference in 
attrition between patients treated with lenalidomide or 
thalidomide­based induction was observed. The number 
of patients achieving partial or minimal response to each 
induction triplet entering the CVD randomisation were 
200 (60%) of 333 in the CTD group, 167 (61%) of 276 in 
the CRD group, 118 (34%) of 345 in the attenuated CTD 
group, and 98 (37%) of 263 in the attenuated CRD group. 
The induction intensification randomisation occurred 
between Nov 15, 2010, and July 28, 2016. 289 patients 
were assigned to receive CVD and 294 patients were 
assigned to no CVD (figure 1), of which 367 were enrolled 
in the transplantation­eligible pathway and 216 were 
enrolled in the transplantation­ineligible pathways. 
Patient and disease characteristics were well balanced 
between groups (table 1). The median time from 
induction therapy randomisation to CVD randomisation 
was 5·7 months (IQR 4·7–6·9) in the CVD group versus 
5·8 months (4·6–6·7) in the no CVD group.
Median follow­up after randomisation was 29·7 months 
(IQR 17·0–43·5): 31·0 months (IQR 19·2–45·5) for 
transplantation­eligible patients and 27·3 months 
(IQR 14·7–40·9) for transplantation­ineligible patients. 
CVD group, 
N=289
No CVD group, 
N=294
Age, years 66·0 (57·0–72·0) 66·0 (57·0–72·0)
Age group
≤65 years 147 (51%) 152 (52%)
>65 years 142 (49%) 142 (48%)
Sex
Male 175 (61%) 158 (54%)
Female 114 (39%) 136 (46%)
Ethnicity
White 271 (94%) 263 (89%)
Black (eg, Black Caribbean, 
Black African)
5 (2%) 10 (3%)
Asian (eg, Indian, 
Pakistani, Bangladeshi)
4 (1%) 7 (2%)
Other 5 (2%) 3 (1%)
Unknown 4 (1%) 11 (4%)
International Staging System
I 95 (33%) 90 (31%)
II 129 (45%) 126 (43%)
III 51 (18%) 60 (20%)
Unknown 14 (5%) 18 (6%)
Immunoglobulin subtype
IgG 228 (79%) 219 (74%)
IgA 46 (16%) 57 (19%)
IgM 0 (0%) 0 (0%)
IgD 0 (0%) 2 (<1%)
Light chain only 15 (5%) 15 (5%)
Non-secretor 0 (0%) 1 (<1%)
Cytogenetic risk available 129 (45%) 131 (45%)
Cytogenetic risk*
Standard 79 (61%) 71 (54%)
High 32 (25%) 48 (37%)
Ultra-high 18 (14%) 12 (9%)
Creatinine, μmol/L 84·0 (71·0–100·0) 84·0 (70·0–104·0)
Unknown 0 (0%) 1 (<1%)
Transplantation eligibility
Transplantation eligible 183 (63%) 184 (63%)
Transplantation ineligible 106 (37%) 110 (37%)
Induction therapy
CRD 85 (29%) 82 (28%)
CTD 98 (34%) 102 (35%)
CRD attenuated dose 49 (17%) 49 (17%)
CTD attenuated dose 57 (20%) 61 (21%)
Time from induction 
randomisation to CVD 
randomisation, months
5·7 (4·7–6·9) 5·8 (4·6–6·7)
Data are median (IQR) or n (%). C=cyclophosphamide. D=dexamethasone. 
R=lenalidomide. T=thalidomide. V=bortezomib. *High risk was defined as 
gain(1q), t(4;14), t(14;16), t(14;20), or del(17p), and ultra-high risk was defined as 
having two or more of these abnormalities. Percentages calculated as percentage 
of risk available.
Table 1: Baseline characteristics
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Figure 2: Progression-free and overall survival in the intention-to-treat population
(A) Progression-free survival. (B) Overall survival. CVD=cyclophosphamide, bortezomib, and dexamethasone.
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For the primary analyses, 131 (45%) of 289 patients in the 
CVD group and 170 (58%) of 294 patients in the no 
CVD group had disease progression or died. Median 
progression­free survival was 30 months (95% CI 25–36) 
in the CVD group and 20 months (15–28) in the no CVD 
group (HR 0·60, 95% CI 0·48–0·75, p<0·0001; figure 2A). 
Similar results were seen in the trans plantation­eligible 
pathway: median progression­free survival was 48 months 
(95% CI 35–not reached) in the CVD group and 
28 months (22–33) in the no CVD group (HR 0·50, 
95% CI 0·36–0·68, p<0·0001; appendix p 9); and the 
transplantation­ineligible pathway: median progression­
free survival was 20 months (95% CI 15–23·7) in the CVD 
group and 9 months (6–15) in the no CVD group 
(HR 0·73, 95% CI 0·52–1·02, p=0·061; appendix p 9).
There was some evidence that the proportional hazards 
assumption was violated overall (p<0·0001) and in the 
transplantation­eligible (p=0·059) and transplantation­
ineligible pathway (p=0·0010), suggesting the treatment 
effect was not consistent over time. Outcomes were, 
therefore, further investigated using the restricted mean 
survival time method. This confirmed a significant benefit 
of CVD over no CVD in the overall population and in the 
transplantation­eligible pathway. This analysis further 
suggested a significant early benefit for CVD in the 
transplantation­ineligible pathway, which was lost at later 
time points (full analysis is presented in the appendix p 2).
54 (18%) of 289 patients died in the CVD group and 
54 (19%) of 294 patients in the no CVD group. Median 
overall survival was not reached in either group. 3­year 
overall survival was 77·3% (95% CI 71·0–83·5) in the CVD 
group and 78·5% (72·3–84·6) in the no CVD group. No 
difference was detected between CVD and no CVD for 
overall survival (HR 0·98, 95% CI 0·67–1·43, p=0·93; 
figure 2B). The most common cause of death was tumour 
load (appendix p 5). Similar results were seen in the 
transplantation­eligible pathway: median overall survival 
was not reached in the CVD group and not reached in the 
no CVD group and 3­year overall survival was 81·5% 
(95% CI 74·4%–88·6%) in the CVD group and 81·2% 
(74·4%–87·9%) in the no CVD group (HR 0·83, 95% CI 
0·50–1·36, p=0·45; appendix p 10); and the trans plantation­
ineligible pathway: median overall survival was not reached 
in the CVD group and not reached in the no CVD group 
and 3­year overall survival was 77·3% (95% CI 71·0–83·5) 
in the CVD group and 78·5% (72·3–84·6) in the no CVD 
group (HR 1·26, 95% CI 0·70–2·27, p=0·44; appendix p 10).
78 (27%) of 289 patients in the CVD group and 
88 (30%) of 294 patients in the no CVD group had 
second disease progression or died. Median progression­
free survival 2 was 52 months (95% CI 49–56) with CVD 
and 48 months (37–not reached) with no CVD (HR 0·83, 
95% CI 0·61–1·22, p=0·22; appendix p 11). Similar 
results were seen in the transplantation­eligible 
pathway: median progression­free survival 2 was not 
reached with CVD and 53 months (49–not reached) with 
no CVD (HR 0·91, 95% CI 0·46–1·04, p=0·077; 
appendix p 11) and the transplantation­ineligible 
pathway: median progression­free survival 2 was 
42 months (33–56 months) with CVD and 37 months 
(30–49) with no CVD (HR 1·06, 95% CI 0·66–1·70, 
p=0·81; appendix p 11).
After induction After 
intensification
After autologous stem cell 
transplantation
CVD group, 
N=289
No CVD group, 
N=294
CVD group, 
N=289
CVD group, 
N=133
No CVD group, 
N=119
Very good partial 
response or better
13 (4%) 12 (4%) 123 (43%) 87 (65%) 47 (39%)
Complete response 1 (<1%) 0 (0%) 10 (3%) 19 (14%) 7 (6%)
Very good partial 
response
12 (4%) 12 (4%) 113 (39%) 68 (51%) 40 (34%)
Partial response 243 (84%) 247 (84%) 113 (39%) 35 (26%) 65 (55%)
Minimal response 24 (8%) 22 (7%) 4 (1%) 2 (2%) 2 (2%)
Stable disease 0 (0%) 2 (<1%) 0 (0%) 0 (0%) 0 (0%)
Progressive disease 3 (1%) 9 (3%) 11 (4%) 3 (2%) 2 (2%)
Unavailable* 6 (2%) 2 (<1%) 38 (13%) 6 (5%) 3 (3%)
Data are n (%). CVD=cyclophosphamide, bortezomib, and dexamethasone. *After intensification, Unavailable included 
no CVD received (n=17), CVD continuing (n=6), and death within 60 days of starting CVD (n=1); after autologous stem 
cell transplantation, Unavailable included death within 100 days after melphalan (n=1).
Table 2: Response by central review
Grade 1–2 Grade 3 Grade 4
Haematological
Neutropenia 56 (20%) 15 (5%) 3 (1%)
Anaemia 193 (70%) 8 (3%) 0 (0%)
Thrombocytopenia 110 (40%) 13 (5%) 6 (2%)
Infections
Upper respiratory infection 23 (8%) 2 (<1%) 0 (0%)
Lung infection 18 (7%) 12 (4%) 1 (<1%)
Other 12 (4%) 4 (1%) 0 (0%)
Neurological
Peripheral sensory neuropathy 155 (56%) 9 (3%) 1 (<1%)
Peripheral motor neuropathy 44 (16%) 3 (1%) 0 (0%)
Gastroenterological
Constipation 98 (36%) 1 (<1%) 0 (0%)
Diarrhoea 52 (19%) 5 (2%) 0 (0%)
Nausea 44 (16%) 0 (0%) 0 (0%)
Other
Fatigue 83 (30%) 3 (1%) 0 (0%)
Lethargy 20 (7%) 1 (<1%) 0 (0%)
Back pain 32 (12%) 3 (1%) 0 (0%)
Oedema limbs 35 (13%) 0 (0%) 0 (0%)
Hypotension 17 (6%) 3 (1%) 0 (0%)
Dizziness 16 (6%) 4 (1%) 0 (0%)
Data are n (%). The table includes all grade 1–2 adverse reactions occurring in at 
least 10% of patients and all grade 3 or 4 adverse reactions occurring at least 1% 
of patients in the CVD group (N=275). No grade 5 adverse reactions occurred. 
Sites were asked to report adverse reactions for patients taking the CVD and 
serious adverse events in all patients. Serious adverse events are shown in the 
appendix (p 7). CVD=cyclophosphamide, bortezomib, and dexamethasone.
Table 3: Adverse events
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Of the 289 patients randomly assigned to CVD, 243 (84%) 
had partial response and 24 (8%) had minimal response at 
the time of randomisation (at central review, 1 [<1%] had 
complete response, 12 [4%] had very good partial response, 
and 3 [1%] had stable or progressive disease); a similar 
distribution of responses was seen in the no CVD group 
(table 2). After CVD, 123 (42·6%, 95% CI 36·8–48·4) of 
289 patients had very good partial response or better, with 
ten (3·5%, 1·7–6·3) achieving complete response and 
113 (39·1%, 33·4–44·9) achieving very good partial 
response (table 2). The proportion of patients achieving 
very good partial response or better after CVD was similar 
regardless of the induction regimen received (43 [44%] of 
98 for CTD, 39 [46%] of 85 for CRD, 22 [39%] of 57 for 
attenuated CTD, and 19 [39%] of 49 for attenuated CRD; 
appendix p 6). Among transplantation­eligible patients, 
response rates improved after autologous haemopoietic 
stem cell transplantation in both those randomly assigned 
to CVD and no CVD, but the final depth of response was 
greater in patients who received pre­transplant CVD. In 
the CVD group, 19 (14·3%, 8·8–21·4) of 133 patients 
achieved a complete response after ASCT and 68 (51·1%, 
42·3–59·9) achieved a very good partial response (table 2). 
In the no CVD group, seven (5·9%, 2·4–11·7) of 
119 achieved a complete response and 40 (33·6%, 
25·2–42·9) achieved a very good partial response (table 2).
(Figure 3 continues on next page)
Sex
Male
Female
Age (years)
≤65
>65
International Staging System
Stage I
Stage II
Stage III
Not available
Induction
CTD or attenuated CTD
CRD or attenuated CRD
Response before intensification
Minimal response
Partial response
t(4;14)
Present
Absent
t(14;16)
Present
Absent
del(17p)
Present
Absent
gain(1q)
Present
Absent
Cytogenetic risk
Standard
High
Ultra-high
Not available
Pathway
Transplantation eligible
Transplantation ineligible
Overall
A
No CVD group, n/N
 86/158
 84/136
 80/152
 90/142
 42/90
 72/126
 44/60
 12/18
 95/163
 75/131
 17/26
 153/268
 7/10
 77/121
 2/2
 82/129
 12/14
 72/117
 33/46
 51/85
 42/71
 31/48
 11/12
 86/163
 97/184
 73/110
 170/294
CVD group, n/N
 88/175
 43/114
 54/147
 77/142
 41/95
 56/129
 26/51
 8/14
 74/155
 57/134
 10/24
 121/265
 12/19
 49/110
 2/2
 59/127
 5/7
 56/122
 25/40
 36/89
 30/79
 18/32
 13/18
 70/160
 65/183
 66/106
 131/289
Hazard ratio (95% CI)
0·71 (0·53–0·96)
0·47 (0·32–0·67)
0·47 (0·33–0·67)
0·66 (0·48–0·89)
0·74 (0·48–1·13)
0·64 (0·45–0·92)
0·39 (0·23–0·64)
0·40 (0·12–1·28)
0·62 (0·46–0·84)
0·55 (0·39–0·78)
0·41 (0·18–0·95)
0·61 (0·48–0·77)
0·22 (0·07–0·71)
0·45 (0·31–0·65)
··
0·46 (0·33–0·64)
0·23 (0·05–1·01)
0·49 (0·34–0·70)
0·51 (0·30–0·89)
0·44 (0·28–0·68)
0·45 (0·28–0·73)
0·40 (0·21–0·76)
0·18 (0·06–0·49)
0·73 (0·53–1·00)
0·50 (0·36–0·68)
0·72 (0·52–1·01)
0·60 (0·48–0·75)
P. (het)
0·0813
0·2157
0·3746
0·2235*
0·6837
0·6001
0·3494
0·5188
0·5295
0·3913
0·1163
0·7073*
0·0806
0·01 0·10 0·50 1·00
Hazard ratio
2·00
Articles
www.thelancet.com/haematology   Vol 6   December 2019 e626
Patients received a median of four (range 3–5) cycles of 
CVD. 187 (65%) of 289 patients stopped due to achieving 
maximum response, whereas 34 (12%) stated un­
acceptable toxicity as the only or contributory reason for 
stopping. 144 (50%) of 289 patients had a dose 
modification during CVD treatment with cyclophos­
phamide modified in 58 (20%), bortezomib in 115 (40%) 
and dexamethasone in 74 (26%). The most common 
adverse events reported in the CVD group were anaemia 
(201 [73%] of 275), peripheral sensory neuropathy 
(165 [60%]), thrombocytopenia (129 [47%]), constipation 
(99 [36%]), neutropenia (74 [27%]), and diarrhoea 
(57 [21%]; table 3). Most events were mild­to­moderate in 
severity, with small numbers of grade 3 or higher adverse 
events (table 3). Other grade 3 or higher adverse events 
of note were lung infections (13 [5%]). Serious adverse 
events occurred in 103 (37%) patients during CVD 
intensification (appendix p 7), andd 58 (28%) patients 
had a serious adverse event related to study treatment. 
The most common treatment­related serious adverse 
event was infection, accounting for 42 (59%) of the 
71 serious adverse events in the CVD group.
Subgroup analyses of progression­free survival and 
overall survival according to baseline characteristics were 
Figure 3: Subgroup analysis of progression-free and overall survival
(A) Progression-free survival. (B) Overall survival. C=cyclophosphamide. D=dexamethasone. NE=Not estimable. R=lenalidomide. T=thalidomide. V=bortezomib. 
*Likelihood ratio test for heterogeneity of effect among patients with subgroup data available.
Sex
Male
Female
Age (years)
≤65
>65
International Staging System
Stage I
Stage II
Stage III
Not available
Induction
CTD or attenuated CTD
CRD or attenuated CRD
Response before intensification
Minimal response
Partial response
t(4;14)
Present
Absent
t(14;16)
Present
Absent
del(17p)
Present
Absent
gain(1q)
Present
Absent
Cytogenetic risk
Standard
High
Ultra-high
Not available
Pathway
Transplantation eligible
Transplantation ineligible
Overall
B
No CVD group, n/N
 28/158
 26/136
 26/152
 28/142
 12/90
 20/126
 16/60
 6/18
 28/163
 26/131
 5/26
 49/268
 5/10
 24/121
 1/2
 28/129
 8/14
 21/117
 12/46
 17/85
 11/71
 11/48
 7/12
 25/163
 33/184
 21/110
 54/294
CVD group, n/N
 36/175
 18/114
 22/147
 32/142
 15/95
 24/129
 14/51
 1/14
 27/155
 27/134
 3/24
 51/265
 4/19
 18/110
 1/2
 21/127
 2/7
 20/122
 12/40
 10/89
 8/79
 9/32
 5/18
 32/160
 30/183
 24/106
 54/289
Hazard ratio (95% CI)
1·08 (0·66–1·77)
0·82 (0·44–1·51)
0·77 (0·43–1·36)
1·20 (0·72–2·01)
1·06 (0·48–2·31)
1·22 (0·67–2·24)
0·89 (0·41–1·95)
0·24 (0·02–2·49)
0·99 (0·58–1·68)
1·00 (0·58–1·71)
0·53 (0·12–2·37)
1·02 (0·69–1·51)
0·05 (0·01–0·54)
0·74 (0·40–1·36)
1·00 (0·00–NE)
0·66 (0·37–1·17)
0·07 (0·01–0·75)
0·86 (0·47–1·59)
1·28 (0·56–2·91)
0·49 (0·22–1·08)
0·64 (0·25–1·63)
1·07 (0·43–2·64)
0·52 (0·12–2·24)
1·39 (0·82–2·36)
0·83 (0·50–1·36)
1·26 (0·70–2·27)
0·98 (0·67–1·43)
P. (het)
0·5733
0·2576
0·4713
0·9115*
0·9987
0·4697
0·0982
0·2407
0·1047
0·0872
0·2316
0·6097*
0·2299
0·01 0·10 0·50 1·00
Hazard ratio
2·00
Articles
e627 www.thelancet.com/haematology   Vol 6   December 2019
consistent with the results in the overall population 
(figure 3). In all subgroups, progression­free survival 
consistently favoured CVD versus no CVD irrespective of 
sex, age, induction therapy, and response at CVD 
randomisation. At initial randomisation, genetic risk had 
been evaluated in 260 (45%) of 583 patients (129 CVD; 
131 no CVD). 150 (58%) of the 260 evaluable patients had 
standard risk, 80 (31%) had high risk, and 30 (12%) had 
ultra­high risk. The benefit of CVD versus no CVD in 
terms of progression­free survival was also seen across 
cytogenetic risk groups, including those with standard 
risk (HR 0·45, 95% CI 0·28–0·73), high risk (HR 0·40, 
95% CI 0·21–0·76), and ultra­high risk (HR 0·18, 95% CI 
0·06–0·49; appendix p 13) with no significant 
heterogeneity between subgroups (pheterogeneity=0·71) and 
numerically smaller HRs in the high risk and ultra­high 
risk cohorts, although the numbers of patients were 
small, particularly in the ultra­high risk cohort.
Discussion
This study showed that additional therapy with CVD 
improved the depth of response for patients with newly 
diagnosed multiple myeloma with a suboptimal response 
to an immunomodulatory drug triplet combination, 
leading to marked improvements in progression­free 
survival compared with patients not receiving CVD 
intensification but without any difference in overall 
survival. The depth of response was very good partial 
response or better in 42·6% (95% CI 36·8–48·4) of 
patients treated with CVD. Median progression­free 
survival improved by 20 months in transplantation­
eligible patients (HR 0·50, 95% CI 0·36–0·68) and 
12 months in transplantation­ineligible patients 
(HR 0·73, 95% CI 0·52–1·02). Overall survival did not 
differ; however, median overall survival was not reached 
in either group at the time of analysis and after additional 
follow­up this endpoint will be reanalysed.
The absence of overall survival difference might have 
been confounded by the use of therapy after relapse, for 
example, which was not pre­specified. Outcomes in the no 
CVD group might also have been affected by subsequent 
treatment within the trial. Although progression free 
survival improved with lenalidomide versus observation 
in all patients in the maintenance randomisation, patients 
receiving no CVD appeared to have an even greater benefit 
than those who had CVD or were not randomly assigned 
(no CVD HR 0·26 [95% CI 0·17–0·40] vs CVD HR 0·48 
[0·30–0·76] vs not randomly assigned HR 0·49 [0·43–0·57] 
pheterogeneity=0·011).8
The benefit of CVD therapy in terms of progression­free 
survival was consistent across subgroups and persisted 
after autologous haemopoietic stem cell transplantation in 
transplantation­eligible patients. The response rates after 
transplantation for the CVD and no CVD patients show 
that autologous haemopoietic stem cell transplantation 
alone can improve suboptimal initial response, but this 
can be significantly further improved by the use of 
pre­transplant intensifi cation. The beneficial effect of 
CVD intensification on PFS appeared to be independent 
of cytogenetic risk status assessed centrally (with central 
results not fed back to local centres). These results are 
consistent with previous studies that suggest an additional 
benefit for proteasome inhibition particularly in the t(4;14) 
or del(17p) subsets of disease.21,22
Statistically, evidence suggested that the hazard for not 
receiving CVD was not constant over time and, therefore, 
that the proportional hazards assumption was violated. 
This effect appeared more marked in the transplantation­
ineligible pathway. Therefore, as prespecified in the 
statistical analysis plan, the restricted mean survival time 
method was used to confirm the results from the Cox 
regression analysis. This analysis confirmed the 
progression­free survival benefit associated with early 
exposure to CVD in transplantation­ineligible patients, 
possibly reflecting the effects of subsequent and later­
line therapies in this patient subgroup.
From a biological perspective, our results are consistent 
with the concept that resistance to initial therapy is based 
on the specific therapy used. This resistance can be 
overcome by switching to a chemotherapy regimen with 
an alternate mechanism of action. We found that the 
adverse prognostic effect of poor initial response can be 
overcome and is not an inherent feature of the cancer itself 
but rather of the therapy administered. Analysis of patients 
within the trial achieving stable disease or progressive 
disease to immunomodulatory triplet induction who all 
received CVD intensification will explore this concept 
further and will be published separately. Additionally, in 
long­term follow­up, we plan to investigate the differences 
between achieving complete response or very good partial 
response to initial induction in contrast to only achieving it 
after CVD intensification. Minimal residual disease 
analysis was also done and this data will be presented 
separately.
In contrast to our use of induction intensification, 
two studies have examined the use of post­transplant 
consolidation. In the Stamina BMT CTN 0702 study,23 
patients were treated with initial therapy at investigators 
discretion followed by randomisation before autologous 
haemopoietic stem cell transplantation to one of three 
strategies: transplantation followed by lenalidomide 
maintenance, two autologous stem cell transplants 
followed by lenalidomide maintenance, or transplantation 
followed by post­transplant consolidation with bortezomib, 
lenalidomide, and dexamethasone (VRD) and then by 
lenalidomide maintenance. No difference in progression­
free survival or overall survival was identified between 
randomisation groups. In the EMN02 study,24 patients 
were enrolled before commencing treatment and treated 
with four cycles of CVD induction before being randomly 
assigned to autologous haemopoietic stem cell 
transplantation (one or two transplants depending on 
centre) or four cycles of bortezomib, melphalan, and 
prednisolone. There was a subsequent randomisation 
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between two cycles of VRD or no consolidation. All 
patients received lenalidomide maintenance. In this study, 
post­transplant VRD consolidation before lena lidomide 
main tenance improved progression­free survival 
compared with maintenance alone (HR 0·78; p=0·045). 
The preliminary overall survival results indicated 
comparable 3­year overall survival with (86%) and without 
consolidation (87%). One of the key differences between 
studies was the initial induction therapy administered. In 
Stamina BMT CTN 0702, maximum response to induction 
therapy was more likely to have been achieved before 
autologous haemopoietic stem cell transplantation due to 
a lack of fixed duration of induction therapy. Similar to our 
study, patients had a median of 5 months (range 
2–14 months) between initial therapy and registration and 
around 15% of patients had received more than 
one previous regimen, suggesting therapy changes in 
patients with a suboptimal initial response. In contrast, 
patients in EMN02 received a fixed four cycles of CVD 
given in 21­day cycles, equating to 3 months of therapy. 
Taken together, these two studies support the conclusions 
of our study and suggest that maximising treatment 
response, either before or after transplant, is an important 
endpoint of therapy.
One limitation of the Myeloma XI study might be the 
induction regimens used, CRD or CTD combinations 
followed by a proteasome­inhibitor­based intensification 
regimen. The trial was designed in this manner owing to 
the UK standard of care at the time with no access to 
bortezomib either alone or in combination with 
immunomodulatory drugs. However, the outcomes for 
patients in the Myeloma XI trial do not substantially differ 
from other novel combinations. In the IFM 2009 study,25 
700 transplantation­eligible patients were randomly 
assigned to either three cycles of VRD followed by 
autologous haemopoietic stem cell transplantation and two 
cycles of VRD or VRD for eight cycles without autologous 
haemopoietic stem cell transplantation. The study25 
supported the use of upfront autologous haemopoietic 
stem cell transplantation, with the median progression­free 
survival being longer for patients who received RVD and 
transplantation compared with those who received RVD 
alone (50 vs 36 months, HR 0·65, 95% CI 0·53–0·80, 
p<0·001), although overall survival was similar in both 
treatment groups. The results obtained in Myeloma XI are 
not dissimilar. For example, the median progression­free 
survival from CVD randomisation (ie, not including the 
duration of previous induction cycles) was 48 months for 
those receiving CVD consolidation in Myeloma XI 
compared to 50 months from the start of induction for 
those who received VRD plus autologous haemopoietic 
stem cell transplantation in IFM 2009 (appendix p 8). VRD 
is not widely reimbursed outside of the USA, where the 
combinations used in this study remain pertinent. 
Furthermore, even in the setting of VRD, a proportion of 
patients do not respond well and so the findings of 
Myeloma XI would support personalising therapy by 
adding additional agents of a different class to induction in 
the absence of a deep initial response. About half of the 
patients in the Myeloma XI trial with partial or minimal 
response after induction therapy discontinued the study 
before intensification randomisation for various reasons 
and are, therefore, not included in the analysis presented 
here. These reasons included progressive disease and 
death, but also off­study treatment. Although further details 
for each individual patient withdrawing consent were not 
collected, we believe these withdrawals might have been 
driven by investigator and patient discomfort with 
delivering intensification to patients with responses very 
close to very good partial response but not quite meeting it 
or, conversely, not delivering intensification to patients with 
a response of only minimal response to initial induction. 
The substantial number of patients not reaching trial 
randomisation supports the use of combination therapies 
upfront to maximise response and improve outcomes, and 
these are now standard of care in the UK with the 
combination bortezomib, thalidomide, and dexamethasone.
Taken together our data suggest that, in the case of 
suboptimal response to initial treatment, agent class 
should be switched rapidly with the aim of response 
intensification. Although patients who do not respond to 
the induction therapy might still benefit from autologous 
haemopoietic stem cell transplantation,26 these data 
support the maximisation of response before 
transplantation, given that the depth of response is 
associated with improved outcomes.
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